Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
52 hedge funds and large institutions have $125M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
21% more funds holding
Funds holding: 43 → 52 (+9)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less capital invested
Capital invested by funds: $146M → $125M (-$20.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
+$2.53M |
| 2 |
LFWA
LBJ Family Wealth Advisors
Austin,
Texas
|
+$2.28M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$2.18M |
| 4 |
Millennium Management
New York
|
+$1.1M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$874K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.84M |
| 2 |
Goldman Sachs
New York
|
-$225K |
| 3 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$148K |
| 4 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
-$101K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$49.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BlackRock
New York
| $5K | – | – | – |
|
52
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.04K | +41 | New |
|
|
53
Goldman Sachs
New York
| – | -$225K | -8,542 | Closed |
|
RETA Hedge Fund Activity: Q4 2016 in Review
52 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2016, worth a combined $125M — down 14% from $146M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RETA positions and 1 closed out — a net gain of 9 holders — while 25 added to existing stakes and 8 trimmed.
The largest buyer was Paragon Associates & Paragon Associates II Joint Venture, adding an estimated $2.53M. The largest seller was Fidelity Investments, cutting an estimated $7.84M.
- 52 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2016, up from 43 in Q3 2016.
- Funds reported $125M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2016, down 14% quarter-over-quarter.
- 10 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2016 and 1 closed out, a net change of +9 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q4 2016 was Paragon Associates & Paragon Associates II Joint Venture, an estimated $2.53M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2016 was Fidelity Investments, an estimated $7.84M sold.
Based on aggregated 13F filings for Q4 2016.